James McNally - GenMark Diagnostics President
President
Mr. James B. McNally is Senior Vice President, Sales and Marketing of the company. Mr. McNally previously served as Senior Vice President, Marketing and Business Development from October 2016 to August 2018. Prior to joining the Company, Mr. McNally served as Vice President, Marketing and Strategy for Genalyte, Inc., a diagnostics company that is developing an immunoassay platform for near patient testing, from May 2016 to October 2016. From September 2010 to May 2016, Mr. McNally held roles of increasing responsibility with Volcano Corporation and Phillips Volcano, including most recently Director of Marketing and Systems Segment Leader. Prior to joining Volcano Corporationrationration, Mr. McNally held engineering roles with Boston Scientific and Goodrich Corporation and worked in Morgan Stanleys investment banking division since 2018.
Age | 38 |
Tenure | 6 years |
Professional Marks | MBA |
Phone | 760 448-4300 |
Web | www.genmarkdx.com |
GenMark Diagnostics Management Efficiency
The company has return on total asset (ROA) of (2.63) % which means that it has lost $2.63 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.06) %, meaning that it created substantial loss on money invested by shareholders. GenMark Diagnostics' management efficiency ratios could be used to measure how well GenMark Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 87.14 M in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. GenMark Diagnostics has a current ratio of 3.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GenMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, GenMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GenMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GenMark to invest in growth at high rates of return. When we think about GenMark Diagnostics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Found 12 records | PRESIDENT Age | ||
James Hamman | Artisan Partners Asset | 54 | |
Sarah Johnson | Artisan Partners Asset | 52 | |
Ariel Gorelik | AmTrust Financial Services | 43 | |
Eileen Kwei | Artisan Partners Asset | 45 | |
Stephen Ungar | AmTrust Financial Services | 60 | |
Jason Gottlieb | Artisan Partners Asset | 54 | |
Prashanth Gangu | Siriuspoint | 40 | |
David Saks | AmTrust Financial Services | 56 | |
Dean Patenaude | Artisan Partners Asset | 52 | |
Ronald Pipoly | AmTrust Financial Services | 56 | |
Adam Karkowsky | AmTrust Financial Services | 48 | |
Christopher Longo | AmTrust Financial Services | 42 |
Management Performance
Return On Equity | -35.06 | |||
Return On Asset | -2.63 |
GenMark Diagnostics Leadership Team
Elected by the shareholders, the GenMark Diagnostics' board of directors comprises two types of representatives: GenMark Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GenMark. The board's role is to monitor GenMark Diagnostics' management team and ensure that shareholders' interests are well served. GenMark Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GenMark Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
James McNally, Senior Vice President Marketing and Business Development | ||
Michael Gleeson, Sr. VP of North American Commercial Operations | ||
Brian Mitchell, Senior Vice President Operations | ||
Kevin OBoyle, Independent Director | ||
Jennifer Williams, Sr. VP of HR | ||
Scott Mendel, CFO | ||
Ingo Chakravarty, Sr. VP of International | ||
James Fox, Independent Director | ||
Jon Kayyem, Founder and Sr. VP of RandD | ||
Eric Stier, Senior Vice President General Counsel, Secretary | ||
Michael Kagnoff, Director | ||
Hany Massarany, CEO and President and Director | ||
Lisa Giles, Director | ||
Daryl Faulkner, Independent Director | ||
Johnny Ek, CFO |
GenMark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GenMark Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -35.06 | |||
Return On Asset | -2.63 | |||
Profit Margin | (10.87) % | |||
Operating Margin | (4.11) % | |||
Current Valuation | 1.71 B | |||
Shares Outstanding | 73.59 M | |||
Shares Owned By Insiders | 4.72 % | |||
Shares Owned By Institutions | 95.28 % | |||
Number Of Shares Shorted | 5.56 M | |||
Price To Earning | (6.42) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in GenMark Stock
If you are still planning to invest in GenMark Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GenMark Diagnostics' history and understand the potential risks before investing.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets |